2017
Release time：2017-01-01 15:43
The joint-stock company has been established, and its approval for listing on the National Equities Exchange and Quotations has been approved
GT0918 (Proxalutamide tablets) project has obtained clinical trials approval for breast cancer indications in China, and phase I/Ib clinical trials have been launched
GT0918 (Proxalutamide tablets) project has been awarded as the National Special Project for "Significant Novel Drugs Development" during the 13th Five-Year Plan period
recommend News
2025-06-25
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn